Russell Spjut, PharmD, director, formulary management, Magellan Rx Management, shares insight on the regulatory pathways for emerging PDTs, and discusses some of the work of the Digital Therapeutic Alliance.
Russell Spjut, PharmD, director, formulary management, Magellan Rx Management, shares insight on the regulatory pathways for emerging PDTs, and discusses some of the work of the Digital Therapeutic Alliance.
Russell Spjut, PharmD, director, formulary management, Magellan Rx Management, offers some insight on the difference between digital therapeutics terminology and the current landscape for these products.
Russell Spjut, PharmD, director, formulary management, Magellan Rx Management, offers some insight on the difference between digital therapeutics terminology and the current landscape for these products.
“There is need for additional support to keep the patient engaged and empowered to take ownership and an active role in their health care. I think digital therapeutics are a way to start to bridge that gap where we can have that continuous...
“There is need for additional support to keep the patient engaged and empowered to take ownership and an active role in their health care. I think digital therapeutics are a way to start to bridge that gap where we can have that continuous...
Craig Gravina, chief technology officer, ObvioHealth, sheds some light on the current digital therapeutics landscape, including regulatory challenges, the prescription DTx model, and solutions to improve clinical trial research.
Craig Gravina, chief technology officer, ObvioHealth, sheds some light on the current digital therapeutics landscape, including regulatory challenges, the prescription DTx model, and solutions to improve clinical trial research.
Gary Owens, MD, discusses how payers might develop formularies for prescription digital therapeutics, as well as what metrics may be used to determine their efficacy.
Gary Owens, MD, discusses how payers might develop formularies for prescription digital therapeutics, as well as what metrics may be used to determine their efficacy.
Gary Owens, MD, president, Gary Owens Associates, shares challenges related to covering prescription digital therapeutics with an emphasis on risk- vs value-based contracts.
Gary Owens, MD, president, Gary Owens Associates, shares challenges related to covering prescription digital therapeutics with an emphasis on risk- vs value-based contracts.
Soumya Vishwanath, PharmD, University of Massachusetts Medical School, discusses digital therapeutics, which she says is the next wave of patient care, and highlights why it’s essential to assess how these products may play a role in clinical...
Soumya Vishwanath, PharmD, University of Massachusetts Medical School, discusses digital therapeutics, which she says is the next wave of patient care, and highlights why it’s essential to assess how these products may play a role in clinical...
Alison Darcy, PhD, founder & president, Woebot Health, discusses how the pandemic helped restart the conversation surrounding the need to reform mental health care, and identifies the role digital therapeutics are playing in circumventing the...
Alison Darcy, PhD, founder & president, Woebot Health, discusses how the pandemic helped restart the conversation surrounding the need to reform mental health care, and identifies the role digital therapeutics are playing in circumventing the...
“While it’s important for health care systems to implement protocols that mitigate risk of virus transmission and to devote the time, attention, and resources necessary to fighting the pandemic, we can’t overlook the impact of the pandemic on...
“While it’s important for health care systems to implement protocols that mitigate risk of virus transmission and to devote the time, attention, and resources necessary to fighting the pandemic, we can’t overlook the impact of the pandemic on...
Researchers recently found that patient-reported outcomes (PROs) were no different among patients treated with calcitonin gene-related peptide (CGRP) antagonists or onabotulinumtoxinA (ONA) for the indication of chronic migraine prophylaxis.
Researchers recently found that patient-reported outcomes (PROs) were no different among patients treated with calcitonin gene-related peptide (CGRP) antagonists or onabotulinumtoxinA (ONA) for the indication of chronic migraine prophylaxis.
While the largest insurance companies await their fate at the hands of federal regulators, other plans and investors should pay close attention to the opportunity to acquire divested plans from the two deals.
While the largest insurance companies await their fate at the hands of federal regulators, other plans and investors should pay close attention to the opportunity to acquire divested plans from the two deals.
An autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate recently received clearance from the US Food and Drug Administration (FDA) as an investigational new drug for the treatment of patients with refractory...
An autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate recently received clearance from the US Food and Drug Administration (FDA) as an investigational new drug for the treatment of patients with refractory...
Magnetic resonance-guided focused ultrasound thalamotomy is more cost-effective than continued medical therapy for patients with tremor-dominant Parkinson disease.
Magnetic resonance-guided focused ultrasound thalamotomy is more cost-effective than continued medical therapy for patients with tremor-dominant Parkinson disease.
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Lucille Accetta, PharmD, MBA, MSPH, Senior Vice President of CVS Specialty Operations
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.